Abstract
The treatment of TB DR patients is difficult due to low efficiency and costliness.
Aims: to study dynamics of MBT Drug Resistance to antituberculosis drugs among pulmonary TB patients.
Methods: The study MBT DR among 2579 pulmonary TB patients in Saratov region hospital (2006-2015) has been carried out.
Results: The share of MBT DR patients constitutes 86.2% (67.6% in 2006) (p<0,001). The primary-81.5% (36.6% -2006)(p<0.001); the secondary (83.2%) decreased by 4.8%, chronics-100%.
Still the structure of DR has changed for better. The monoresistance has grown up to 9.0% (3.7%- 2012)(p<0.05), the primary DR became18.5% (8.6%-2012), the secondary–8,4% (3.3%-2011), the increase is recorded even with chronics-5.6%.
MDR has dropped by 16.4% to 50.8% (p<0,001), both primary and secondary MDR has declined to 33.3% (40.0% -2012) and to 48.7% (64.7%-2012) (p<0,001) respectively; among chronics decreased by 17.5% to 66.7% (p<0.05).
DR to Isoniasid decreased by 13.3% to 63.5% (p<0,01): the primary by 5,2% to 51.9%, the secondary-10.9% to 62.2%(p<0.001), among chronic s by 21.2% to 72.2% (p<0.01).
DR to Rifampicin dropped by 10.5% to 60.3% (p<0.05), primary by 3.0% to 37.0%, secondary by 14.2% to 56.3%. DR to Ethambutol fell by 4.5% to 53.4% , the secondary decreased by 8.7% to 49.6%, primary stayed on the same 37.0% level, and it has grown among chronics to 83.3% (70.6%-2011). A slight decline by 5.0% (75.1%) in DR to Streptomycin: primary 59.3%, secondary is unchanged-73.9% and chronics-88,9%.
Conclusion: Positive tendencies have been traced in DR dynamics and structure on the account of monoresistance growth and MDR decline in all groups of patients as well as the resistance decrease to Isoniasid, Rifampicin.
- Copyright ©the authors 2016
